Phase II

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.

Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.

Trial Designed to Test Camsirubicin Against Doxorubicin as First-Line Therapy

Companies from across the globe provide information on agreements and pipeline updates.

Pancreatic cancer is a particularly difficult cancer to treat, and although there have been advances in treatment, it is still an extremely deadly disease. Here’s a look at some recent news concerning pancreatic cancer.

Dicerna Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced it has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA).

Now that Novartis has a competing therapy on the market for spinal muscular atrophy (SMA), Biogen is eager to show why it thinks its Spinraza (nusinersen) is superior.

Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.

AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.

Krystal Biotech, Inc. announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase 1 (GEM-1) study.